We observed that PD-1 blockade was able to markedly extend the survival of ORFV pretreated mice (Fig. 6b), which further supported that oncolytic ORFV can harness GSDME, recruit CTLs and further remodel tumor immune microenvironment. The gene discussed is GSDME; the disease is neoplasm.